'''Levallorphan''' ([[International Nonproprietary Name|INN]], [[British Approved Name|BAN]]) (brand names '''Lorfan''', '''Naloxifan''', '''Naloxiphan'''), also known as '''levallorphan tartrate''' ([[United States Adopted Name|USAN]]), is an [[opioid modulator]] of the [[morphinan]] family used as an [[opioid]] [[analgesic]] and [[opioid antagonist]]/[[antidote]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA731|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=731–}}</ref><ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | pages = | isbn = 3-88763-075-0 | oclc = | doi = | url = https://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA1420pg=PA599#v=onepage&q&f=false}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA164|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=164–}}</ref> It acts as an [[receptor antagonist|antagonist]] of the [[μ-opioid receptor]] (MOR) and as an [[agonist]] of the [[κ-opioid receptor]] (KOR),<ref>{{cite book | page = 602 | author = Goodman & Gilman | title = The Pharmacological Basis of Therapeutics | edition = 10th | publisher = McGraw Hill Medical Publishing | isbn = 978-0-07-135469-1 }}</ref> and as a result, blocks the effects of stronger agents with greater [[intrinsic activity]] such as [[morphine]] whilst simultaneously producing [[analgesia]].<ref name="pmid7562497">{{cite journal |author1=Codd, E. E. |author2=Shank, R. P. |author3=Schupsky, J. J. |author4=Raffa, R. B. | title = Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 274 | issue = 3 | pages = 1263–1270 |date=September 1995 | pmid = 7562497 | doi = }}</ref>

 
As an agonist of the KOR, levallorphan can produce severe mental reactions at sufficient doses including [[hallucination]]s, [[dissociation (psychology)|dissociation]], and other [[psychotomimetic]] effects, [[dysphoria]], [[anxiety]], [[confusion]], [[dizziness]], [[disorientation]], [[derealization]], feelings of [[drunkenness]], [[delusion]]s, paranoia, and bizarre, unusual, or disturbing [[dream]]s.<ref name="Hall2012">{{cite book|author=R.C.W. Hall|title=Psychiatric Presentations of Medical Illness: Somatopsychic Disorders|url=https://books.google.com/books?id=lSX2CAAAQBAJ&pg=PA364|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-7677-4|pages=364–}}</ref><ref>{{cite book|title=American Hospital Formulary Service Drug Information|url=https://books.google.com/books?id=cVFtAAAAMAAJ|year=1984|publisher=authority of the Board of Directors of the American Society of Hospital Pharmacists|page=664}}</ref><ref name="Williams1963">{{cite book|author=John B. Williams|title=Narcotics|url=https://books.google.com/books?id=LYNqAAAAMAAJ|year=1963|publisher=Wm. C. Brown Company|page=203}}</ref>
